Foamix Pharmaceuticals Ltd (FOMX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Foamix Pharmaceuticals Ltd (FOMX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH130230D
  • |
  • Pages: 59
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Foamix Pharmaceuticals Ltd (Foamix), formerly Foamix Ltd is a pharmaceutical company that develops and commercializes proprietary topical drugs for various dermatological therapies. The company's product candidates include FMX101, a minocycline foam which is intended for the treatment of moderate-to-severe acne; FMX 103, for the treatment of rosacea; FMX102, for impetigo; and FDX104, a doxycycline foam for the management of acne-like rash. It also develops various early stage products. The company has partnership with various pharmaceutical companies to develop its product candidates. It has presence in Israel and the US. Foamix is headquartered in Rehovot, Israel.

Foamix Pharmaceuticals Ltd (FOMX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Foamix Pharmaceuticals Ltd, Medical Devices Deals, 2011 to YTD 2017 10

Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Foamix Raises USD5 Million In Venture Financing 12

Partnerships 13

Foamix Enters into Co-Development Agreement with National Eye Institute 13

Foamix Enters Into Collaboration With Arkin Holdings 14

Licensing Agreements 15

Merz North America Enters Into Licensing Agreement With Foamix 15

Equity Offering 16

Foamix Pharma Plans to Raise Funds in Public Offering of Shares 16

Foamix Pharma Prices Public Offering of Shares for USD57 Million 17

Foamix Pharma Raises USD69 Million in Public Offering of Shares 19

Foamix Pharma Raises USD40 Million in IPO of Shares 21

Foamix Rumored To Conduct IPO 23

Foamix Pharmaceuticals Ltd-Key Competitors 24

Foamix Pharmaceuticals Ltd-Key Employees 25

Foamix Pharmaceuticals Ltd-Locations And Subsidiaries 26

Head Office 26

Other Locations & Subsidiaries 26

Recent Developments 27

Financial Announcements 27

Aug 08, 2017: Foamix Reports Second Quarter 2017 Financial Results and Provides Business Update 27

May 09, 2017: Foamix Reports First Quarter 2017 Financial Results and Provides Business Update 31

Feb 22, 2017: Foamix Reports Year End 2016 Financial Results and Provides Business Update 34

Nov 15, 2016: Foamix Reports Third Quarter 2016 Financial Results and Provides Business Update 35

Aug 10, 2016: Foamix Reports Second Quarter 2016 Financial Results and Provides Business Update 42

May 11, 2016: Foamix reports first quarter 2016 financial results and provides business update 46

Mar 03, 2016: Foamix Reports Fiscal Year 2015 Financial Results and Provides Business Update 49

Corporate Communications 50

Jun 29, 2017: Foamix Pharmaceuticals Appoints David Domzalski as Chief Executive Officer 50

May 16, 2016: Foamix Names Dr. Stanley Hirsch as Chairman, and Dr. Dalia Megiddo as a Member of the Board of Foamix Pharmaceuticals 51

Product News 52

05/31/2016: Foamix Pharmaceuticals Announces Publication of Abstract on FDX-104 in the Treatment of EGFRI Induced Rash for the 2016 ASCO Meetin 52

Clinical Trials 53

Nov 28, 2016: Foamix Announces Completion of Patient Enrollment in Phase 3 Acne Trials for Minocycline Foam FMX101 53

Sep 12, 2016: Foamix Announces Positive Topline Results from Phase 2 Trial Evaluating FMX-103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea 54

Sep 09, 2016: Foamix to Announce Topline Results in Phase 2 Clinical Trial of FMX-103 Minocycline Topical Foam for Moderate-to-Severe Papulopustular Rosacea 55

May 09, 2016: Foamix Announces Dosing of First Patient in Phase 3 Acne Studies for Minocycline Foam FMX101 56

May 03, 2016: Foamix Announces Completion of Enrollment in Phase 2 Clinical Trial of Minocycline Foam (FMX103) for Treatment of Papulopustular Rosacea 57

Jan 07, 2016: Foamix Announces Positive Results From Phase 1 Study to Characterize Minocycline Bioavailability of FMX-101 Compared to Solodyn Extended-Release Tablets 58

Appendix 59

Methodology 59

About GlobalData 59

Contact Us 59

Disclaimer 59

List of Figures

Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2

Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2

Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2

Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2

Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Foamix Pharmaceuticals Ltd, Medical Devices Deals, 2011 to YTD 2017 10

List of Tables

Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2

Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Foamix Pharmaceuticals Ltd, Deals By Therapy Area, 2011 to YTD 2017 9

Foamix Pharmaceuticals Ltd, Medical Devices Deals, 2011 to YTD 2017 10

Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Foamix Raises USD5 Million In Venture Financing 12

Foamix Enters into Co-Development Agreement with National Eye Institute 13

Foamix Enters Into Collaboration With Arkin Holdings 14

Merz North America Enters Into Licensing Agreement With Foamix 15

Foamix Pharma Plans to Raise Funds in Public Offering of Shares 16

Foamix Pharma Prices Public Offering of Shares for USD57 Million 17

Foamix Pharma Raises USD69 Million in Public Offering of Shares 19

Foamix Pharma Raises USD40 Million in IPO of Shares 21

Foamix Rumored To Conduct IPO 23

Foamix Pharmaceuticals Ltd, Key Competitors 24

Foamix Pharmaceuticals Ltd, Key Employees 25

Foamix Pharmaceuticals Ltd, Subsidiaries 26

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Foamix Pharmaceuticals Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16143
Site License
USD 500 INR 32285
Corporate User License
USD 750 INR 48428

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com